RBC cuts Axsome Therapeutics price target to $295
RBC Capital cut its price target for Axsome Therapeutics to $295 from $297, according to Benzinga.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
RBC cuts Axsome Therapeutics price target to $295
RBC Capital cut its Axsome Therapeutics price target to $295.00 per share from $297.00.